HAE Haemonetics Corporation
$78.80▲ +0.11%
Unknown
Other
Last sync: just now
Syncing
Key Metrics & Fundamentals
Market Cap
$3.58B
P/E Ratio
38.4
Div Yield
–%
52W Range
47.32 - 87.32
% vs 50 MA
29.64%
% vs 200 MA
24.84%
RSI-14
80.9
MACD Histogram
+1.3900
Beta (1Y vs SPY)
0.35
Free Cash Flow
$53.28M
Gross Rev
$346.35M
Gross Profit
$198.21M
EBITDA
$79.66M
COGS
$148.14M
Operating Exp
$145.87M
Operating Income
$52.34M
EBIT
$52.34M
Pretax Income
-$28.40M
Net Income
-$20.15M
Price & Volume History
Volume (M)
Financial Overview - Income Statement
Quarterly
Mar 2026 (Quarterly)
Social Sentiment
Avg +0.74 · 6 posts
DDNewsDiscussionNTLA beginning to gain serious traction
r/wallstreetbets · Oct 8, 2025
The post discusses a clinical trial (lonvo-z) related to HAE and a positive aspect of the technology (in vivo CRISPR).
positive
+0.70
NewsDiscussionIn vivo CRISPR and potentially major catalysts ahead for NTLA
r/investing · Oct 2, 2025
Mention of HAE and its treatment with in vivo CRISPR contributes to the positive sentiment surrounding NTLA's prospects.
positive
+0.60
NewsDiscussionIONS is About to Break Out
r/wallstreetbets · Aug 19, 2025
The post focuses on a product related to HAE, indicating positive interest in the broader HAE market.
positive
+0.80
NewsTradeDD$KALV ($15.06) KalVista FDA breakout. First oral HAE drug + bullish options setup
r/options · Jul 8, 2025
The post highlights FDA approval, bullish options, and potential price targets indicating strong belief in KALV's future.
positive
+0.80
NewsDDTrade[KALV] FDA APPROVED 🚀 | First-in-class oral HAE drug is here — buckle up
r/wallstreetbets · Jul 7, 2025
The post highlights significant positive developments like FDA approval, market exclusivity, and a potential short squeeze, indicating strong bullish sentiment.
positive
+0.80
Page 1 of 2 (6 total)
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not Financial Advice.
All data, scores, charts, and analysis on this site are provided for informational and educational purposes only
and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
Always consult a qualified financial advisor before making any investment decisions.
See our Legal Notice for full details.